OBJECTIVE: To understand the chemotherapy response program in ovarian cancer cells at deep transcript sequencing levels. METHODS: Two next-generation sequencing technologies--MPSS (massively parallel signature sequencing) and SBS (sequencing by synthesis)--were used to sequence the transcripts of IGROV1 and IGROV1-CP cells, and to sequence the transcripts of a highly chemotherapy responsive and a highly chemotherapy resistant ovarian cancer tissue. RESULTS: We identified 3422 signatures (2957 genes) that are significantly different between IGROV1 and IGROV1-CP cells (P<0.001). Gene Ontology (GO) term GO:0001837 (epithelial-to-mesenchymal transition) and GO:0034330 (cell junction assembly and maintenance) are enriched in genes that are over expressed in IGROV1-CP cells while apoptosis-related GO terms are enriched in genes over expressed in IGROV1 cells. We identified 1187 tags (corresponding to 1040 genes) that are differentially expressed between the chemotherapy responsive and the persistently chemotherapy resistant ovarian cancer tissues. GO term GO:0050673 (epithelial cell proliferation) and GO:0050678 (regulation of epithelial cell proliferation) are enriched in the genes over expressed in the chemotherapy resistant tissue while the GO:0007229 (integrin-mediated signaling pathway) is enriched in the genes over expressed in the chemotherapy sensitive tissue. An integrative analysis identified 111 common differentially expressed genes including two bone morphogenetic proteins (BMP4 and BMP7), six solute carrier proteins (SLC10A3, SLC16A3, SLC25A1, SLC35B3, SLC7A5 and SLC7A7), transcription factor POU5F1 (POU class 5 homeobox 1), and KLK10 (kallikrein-related peptidase 10). A network analysis revealed a subnetwork with three genes BMP7, NR2F2 and AP2B1 that were consistently over expressed in the chemoresistant tissue or cells compared to the chemosensitive tissue or cells. CONCLUSION: Our database offers the first comprehensive view of the digital transcriptomes of ovarian cancer cell lines and tissues with different chemotherapy response phenotypes. Copyright (c) 2010 Elsevier Inc. All rights reserved.
OBJECTIVE: To understand the chemotherapy response program in ovarian cancer cells at deep transcript sequencing levels. METHODS: Two next-generation sequencing technologies--MPSS (massively parallel signature sequencing) and SBS (sequencing by synthesis)--were used to sequence the transcripts of IGROV1 and IGROV1-CP cells, and to sequence the transcripts of a highly chemotherapy responsive and a highly chemotherapy resistant ovarian cancer tissue. RESULTS: We identified 3422 signatures (2957 genes) that are significantly different between IGROV1 and IGROV1-CP cells (P<0.001). Gene Ontology (GO) term GO:0001837 (epithelial-to-mesenchymal transition) and GO:0034330 (cell junction assembly and maintenance) are enriched in genes that are over expressed in IGROV1-CP cells while apoptosis-related GO terms are enriched in genes over expressed in IGROV1 cells. We identified 1187 tags (corresponding to 1040 genes) that are differentially expressed between the chemotherapy responsive and the persistently chemotherapy resistant ovarian cancer tissues. GO term GO:0050673 (epithelial cell proliferation) and GO:0050678 (regulation of epithelial cell proliferation) are enriched in the genes over expressed in the chemotherapy resistant tissue while the GO:0007229 (integrin-mediated signaling pathway) is enriched in the genes over expressed in the chemotherapy sensitive tissue. An integrative analysis identified 111 common differentially expressed genes including two bone morphogenetic proteins (BMP4 and BMP7), six solute carrier proteins (SLC10A3, SLC16A3, SLC25A1, SLC35B3, SLC7A5 and SLC7A7), transcription factor POU5F1 (POU class 5 homeobox 1), and KLK10 (kallikrein-related peptidase 10). A network analysis revealed a subnetwork with three genes BMP7, NR2F2 and AP2B1 that were consistently over expressed in the chemoresistant tissue or cells compared to the chemosensitive tissue or cells. CONCLUSION: Our database offers the first comprehensive view of the digital transcriptomes of ovarian cancer cell lines and tissues with different chemotherapy response phenotypes. Copyright (c) 2010 Elsevier Inc. All rights reserved.
Authors: C Victor Jongeneel; Christian Iseli; Brian J Stevenson; Gregory J Riggins; Anita Lal; Alan Mackay; Robert A Harris; Michael J O'Hare; A Munro Neville; Andrew J G Simpson; Robert L Strausberg Journal: Proc Natl Acad Sci U S A Date: 2003-04-01 Impact factor: 11.205
Authors: Paul Shannon; Andrew Markiel; Owen Ozier; Nitin S Baliga; Jonathan T Wang; Daniel Ramage; Nada Amin; Benno Schwikowski; Trey Ideker Journal: Genome Res Date: 2003-11 Impact factor: 9.043
Authors: Blake C Meyers; Shivakundan Singh Tej; Tam H Vu; Christian D Haudenschild; Vikas Agrawal; Steve B Edberg; Hassan Ghazal; Shannon Decola Journal: Genome Res Date: 2004-08 Impact factor: 9.043
Authors: Sheng Pan; Lihua Cheng; James T White; Wei Lu; Angelita G Utleg; Xiaowei Yan; Nicole D Urban; Charles W Drescher; Leroy Hood; Biaoyang Lin Journal: OMICS Date: 2009-08
Authors: Roya Navab; Juana Maria Gonzalez-Santos; Michael R Johnston; Jiang Liu; Pnina Brodt; Ming-Sound Tsao; Jim Hu Journal: Cancer Res Date: 2004-08-01 Impact factor: 12.701
Authors: E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack Journal: Oncogene Date: 2013-08-12 Impact factor: 9.867
Authors: Boris J Winterhoff; Makayla Maile; Amit Kumar Mitra; Attila Sebe; Martina Bazzaro; Melissa A Geller; Juan E Abrahante; Molly Klein; Raffaele Hellweg; Sally A Mullany; Kenneth Beckman; Jerry Daniel; Timothy K Starr Journal: Gynecol Oncol Date: 2017-01-19 Impact factor: 5.482
Authors: Ribhi Hazin; Kyle B Brothers; Bradley A Malin; Barbara A Koenig; Saskia C Sanderson; Mark A Rothstein; Marc S Williams; Ellen W Clayton; Iftikhar J Kullo Journal: Genet Med Date: 2013-09-12 Impact factor: 8.822
Authors: Britta Stordal; Marion Hamon; Victoria McEneaney; Sandra Roche; Jean-Pierre Gillet; John J O'Leary; Michael Gottesman; Martin Clynes Journal: PLoS One Date: 2012-07-11 Impact factor: 3.240